Effect of Cephagraine Tablets and Nasal Drops in Patients with Migraine and Sinusitis‑Related Headache: An Open‑Label Clinical Trial
Abstract
Background: Headache disorders, particularly migraine and sinusitis‑related headache, are among the leading causes of disability worldwide. Misclassification between these conditions is common, often resulting in inappropriate therapy. Cephagraine, a polyherbal formulation available as tablets and nasal drops, contains herbs with anti‑inflammatory, analgesic, mucolytic, and neuroprotective properties. This study evaluated its efficacy in reducing headache severity and improving quality of life in patients with migraine or sinusitis‑related headache.
Methods: A prospective, interventional trial, open‑label, multi‑center trial enrolled 300 adults (aged 18–60 years), with 150 diagnosed with migraine (ICHD‑3 criteria) and 150 with sinusitis‑related headache (ENT examination using symptom‑based criteria). Participants received Cephagraine tablets (215 mg*2- thrice daily) and nasal drops (two drops per nostril thrice daily) for 15 days. Outcomes were assessed at baseline, Day 8, and Day 15 using validated scales: VAS, MIDAS, HIT‑6 for migraine; SNOT‑22, NOSE, VAS for sinusitis. Statistical analysis employed paired t‑tests, Wilcoxon signed‑rank tests, and ANOVA.
Results: Both groups demonstrated significant reductions in headache severity. VAS scores decreased from 7.8 to 2.6 in migraine patients and from 7.5 to 2.9 in sinusitis patients (p 90% compliance.
Conclusion: Cephagraine tablets and nasal drops significantly reduced headache severity, frequency, and disability in both…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.